Literature DB >> 19118564

Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model.

E M Hendriksen1, P N Span, J Schuuring, J P W Peters, F C G J Sweep, A J van der Kogel, J Bussink.   

Abstract

Tumour growth and spread of tumour cells requires angiogenesis. Incipient angiogenesis is not induced by tumour cell hypoxia but probably by proangiogenic factors. During growth tumours depend on a further induction of vascular development for adequate oxygen and nutrient supply. If the oxygen supply is insufficient, the resulting hypoxia stimulates angiogenesis through upregulation of HIF-1 alpha and VEGF. VEGF upregulation is associated with a poor response to treatment and poor prognosis. The aim of the study was to analyze the interrelationship between hypoxia and angiogenesis during tumour growth. Therefore the tumour vasculature architecture and functional properties of the vessels were studied during subsequent phases of tumour growth in relation to hypoxia and VEGF-expression. Tumours from the human glioblastoma multiforme tumour line E106 were transplanted in athymic mice. Tumours were harvested at 2 days after transplantation and when tumours reached a mean size of 2, 4, 6, 8 and 10 mm. VEGF was present early in the onset of angiogenesis independent of HIF-1 alpha. During tumour growth VEGF increased from 0.94 to 7.27 ng/mg assessed by ELISA. However, there was increasing intratumoural heterogeneity in the architecture of the tumours, even in the largest tumours small well oxygenated areas were detected resembling the relatively well organized architecture of the smallest tumours. The observation that tumour vasculature develops in early phases under normoxic and at later phases under hypoxic conditions with the presence of both conditions in the larger tumours, suggested that anti-angiogenic therapy should be directed towards HIF-1 alpha dependent and HIF 1-alpha independent pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118564     DOI: 10.1016/j.mvr.2008.11.002

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  38 in total

1.  Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.

Authors:  Nathalie Gaspar; Swee Y Sharp; Suzanne A Eccles; Sharon Gowan; Sergey Popov; Chris Jones; Andrew Pearson; Gilles Vassal; Paul Workman
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

2.  Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice.

Authors:  Hironobu Yasui; Shingo Matsumoto; Nallathamby Devasahayam; Jeeva P Munasinghe; Rajani Choudhuri; Keita Saito; Sankaran Subramanian; James B Mitchell; Murali C Krishna
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.

Authors:  Nadia Malkoun; Cyrus Chargari; Fabien Forest; Marie-Jeannette Fotso; Lysian Cartier; Pierre Auberdiac; Julie Thorin; Cécile Pacaut; Michel Peoc'h; Christophe Nuti; Thierry Schmitt; Nicolas Magné
Journal:  J Neurooncol       Date:  2011-07-02       Impact factor: 4.130

Review 4.  Pulsed Electron Paramagnetic Resonance Imaging: Applications in the Studies of Tumor Physiology.

Authors:  Shun Kishimoto; Ken-Ichiro Matsumoto; Keita Saito; Ayano Enomoto; Shingo Matsumoto; James B Mitchell; Nallathamby Devasahayam; Murali C Krishna
Journal:  Antioxid Redox Signal       Date:  2018-01-09       Impact factor: 8.401

5.  Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Authors:  Kathrine Røe; Lars Tg Mikalsen; Albert J van der Kogel; Johan Bussink; Heidi Lyng; Anne H Ree; Laure Marignol; Dag R Olsen
Journal:  Radiat Oncol       Date:  2012-05-23       Impact factor: 3.481

Review 6.  Gene therapy as a potential tool for treating neuroblastoma-a focused review.

Authors:  M D Kumar; A Dravid; A Kumar; D Sen
Journal:  Cancer Gene Ther       Date:  2016-04-15       Impact factor: 5.987

7.  18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.

Authors:  Edwin Chang; Hongguang Liu; Kerstin Unterschemmann; Peter Ellinghaus; Shuanglong Liu; Volker Gekeler; Zhen Cheng; Dietmar Berndorff; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2014-11-07       Impact factor: 12.531

8.  Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside.

Authors:  Ji Ma; Taiji Matsusaka; Hai-Chun Yang; Jianyong Zhong; Nobuaki Takagi; Agnes B Fogo; Valentina Kon; Iekuni Ichikawa
Journal:  Pediatr Res       Date:  2011-07       Impact factor: 3.756

9.  A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level.

Authors:  Raghu Erapaneedi; Vsevolod V Belousov; Michael Schäfers; Friedemann Kiefer
Journal:  EMBO J       Date:  2015-11-23       Impact factor: 11.598

10.  Importance of Serum Copper and Vascular Endothelial Growth Factor (VEGF-A) Levels in Postmenopausal Bleeding.

Authors:  Afshan Rafi; Ramakrishna Devaki; K Sabitha; Shruti Mohanty; Pragna Rao
Journal:  Indian J Clin Biochem       Date:  2012-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.